Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.80 |
| ▸ | THRB | P10828 | 9/20 | 0.77 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.77 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.76 |
| ▸ | GAK | O14976 | 1/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.76 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.76 |
| ▸ | KDR | P35968 | 1/20 | 0.76 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.76 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.76 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.76 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.76 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.76 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.76 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.76 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.76 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.76 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1029466 | 0.99 | TGFBR1 (0.78) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL413323 | 0.93 | TGFBR1 (0.80) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL12922146 | 0.90 | TGFBR1 (0.82) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL23852042 | 0.89 | TGFBR1 (0.80) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL373523 | 0.89 | TGFBR1 (1.00) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL31461242 | 0.89 | TGFBR1 (1.00) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL31461245 | 0.89 | TGFBR1 (0.80) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL5240012 | 0.89 | TGFBR1 (0.80) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL373314 | 0.87 | TGFBR1 (1.00) | TGFBR1THRBMAPK14TGFBR2GAK | |
| SCHEMBL29740016 | 0.87 | TGFBR1 (1.00) | TGFBR1THRBMAPK14TGFBR2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995083-B2 | Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition | HANGZHOU SOLIPHARMA CO., LTD. (CN) | 2021-05-04 | — | — | US | claimed |
| US-20200017470-A1 | COCRYSTAL OF 2-(6-METHYL-PYRIDINE-2-YL)-3-YL-[6-AMIDE-QUINOLINE-4-YL]-5,6-DIHYDRO-4H-PYRROLE[1,2-B]PYRAZOLE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION | HANGZHOU SOLIPHARMA CO., LTD. (CN) | 2020-01-16 | — | — | US | claimed |
| EP-1910370-B1 | A PYRIDIN QUINOLIN SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR | LILLY CO ELI (US) | 2015-04-22 | — | — | EP | claimed |
| US-7834029-B2 | Quinolinyl-pyrrolopyrazoles | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | claimed |
| US-20100120854-A1 | TGF-BETA INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-05-13 | — | — | US | claimed |
| EP-1910370-A1 | A PYRIDIN QUINOLIN SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR | ELI LILLY AND COMPANY (US) | 2008-04-16 | — | — | EP | claimed |
| US-20080027102-A1 | QUINOLINYL-PYRROLOPYRAZOLES | BEIGHT DOUGLAS W | 2008-01-31 | — | — | US | claimed |
| CN-100345852-C | Quinolinyl-pyrrolopyrazoles | LILLY CO ELI (US) | 2007-10-31 | — | — | CN | claimed |
| US-7265225-B2 | Quinolinyl-pyrrolopyrazoles | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | claimed |
| WO-2007018818-A1 | A PYRIDIN QUINOLIN SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | WO | claimed |
| EP-1565471-B1 | QUINOLINYL-PYRROLOPYRAZOLES | LILLY CO ELI (US) | 2006-10-04 | — | — | EP | claimed |
| US-20060040983-A1 | Quinolinyl-pyrrolopyrazoles | ELI LILLY AND COMPANY (US) | 2006-02-23 | — | — | US | claimed |
| CN-1714090-A | Quinolinyl-pyrrolopyrazoles | LILLY CO ELI (US) | 2005-12-28 | — | — | CN | claimed |
| US-11857575-B2 | Mesenchymal stem cell-derived exosomes and their uses | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-01-02 | — | — | US | disclosed |
| CN-110582279-B | Co-crystals of 2- (6-methyl-pyridin-2-yl) -3-yl- [ 6-amido-quinolin-4-yl ] -5, 6-dihydro-4H-pyrrolo [1,2-b ] pyrazole, methods for preparing the same and pharmaceutical compositions | 杭州领业医药科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2022-03-24 | — | — | US | disclosed |
| US-20060040983-A1 | Quinolinyl-pyrrolopyrazoles | ELI LILLY AND COMPANY (US) | 2006-02-23 | — | — | US | disclosed |
| CN-1714090-A | Quinolinyl-pyrrolopyrazoles | LILLY CO ELI (US) | 2005-12-28 | — | — | CN | disclosed |
| EP-1565471-A1 | QUINOLINYL-PYRROLOPYRAZOLES | ELI LILLY AND COMPANY (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048382-A1 | QUINOLINYL-PYRROLOPYRAZOLES | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | TGFB1, TGFBR1, TGFBR2 | TGFBR1 2/4885THRB 89/4885MAPK14 185/4885 |
| US-10995083-B2 | Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition | TGFBR1, WEE2, TGFB2 | TGFBR1 1/4885THRB 1506/4885MAPK14 283/4885 |
| US-11857575-B2 | Mesenchymal stem cell-derived exosomes and their uses | EXOSC9, EXOSC5, EXOSC10 | TGFBR1 2539/4885THRB 4617/4885MAPK14 3026/4885 |
| US-20060040983-A1 | Quinolinyl-pyrrolopyrazoles | SDHA, NQO2, SDHB | TGFBR1 4885/4885THRB 4526/4885MAPK14 2460/4885 |
| US-20080027102-A1 | QUINOLINYL-PYRROLOPYRAZOLES | SDHA, NQO2, SDHB | TGFBR1 4885/4885THRB 4526/4885MAPK14 2460/4885 |
| US-20200017470-A1 | COCRYSTAL OF 2-(6-METHYL-PYRIDINE-2-YL)-3-YL-[6-AMIDE-QUINOLINE-4-YL]-5,6-DIHYDRO-4H-PYRROLE[1,2-B]PYRAZOLE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION | TGFBR1, WEE2, TGFB2 | TGFBR1 1/4885THRB 1506/4885MAPK14 283/4885 |
| US-20100120854-A1 | TGF-BETA INHIBITORS | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885THRB 287/4885MAPK14 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.